Shanghai Henlius Biotech, Inc. Class H · HKEX:2696

Shanghai Henlius Biotech, Inc. Class H — Q3 2023 Earnings Presentation

41 slides from Shanghai Henlius Biotech, Inc. Class H's earnings presentation, November 2023

  1. Slide 1: Henlius (2696.HK) 3Q 2023 Results Investor Presentation

    Henlius(2696.HK)3Q 2023 Results Investor Presentation November 2023 © 2023 Henlius

  2. Slide 2: 3Q 2023 Business Highlights & Company Strategy

    3Q 2023 Business Highlights & 01 Company Strategy © 2023 Henlius

  3. Slide 3: 3Q23: Revenue Tops 1.4B RMB with Net Profit of 168M RMB

    3Q23: Revenue Tops 1.4B RMB with Net Profit of 168M RMB Commercial Operating Revenue BD Pipeline Capacity Cash Flow 1.4B RMB 3 60+ 48KL 240M RMB Commercialization Business Development R&D Manufacturing Financial • Achieved sustainable and • HLX10 (HANSIZHUANG) out- • The study results of ASTRUM- • X

  4. Slide 4: Our Mission and Vision

    Biosimilars Maximize the commercialization value in China and international markets Our Mission and Vision Innovative Drugs Explore new mechanisms, new technology platforms and expand the therapeutic area coverage Affordable Innovation Reliable Quality Globalization Develop towards a biopharma with

  5. Slide 5: The Sales Growth of Marketed Biosimilars Accelerated; Multiple Pipeline Products Planned for Global Presence

    The Sales Growth of Marketed Biosimilars Accelerated; Multiple Pipeline Products Planned for Global Presence • By 3Q 2023 sales revenue of biosimilars reached ~2.5 billion RMB, 43% YoY growth, exceeding the sales revenue of biosimilars in the full year of 2022 • The biosimilar pipeline covered globa

  6. Slide 6: HANSIZHUANG Entered into a New High-growth Stage of Commercialization

    HANSIZHUANG Entered into a New High-growth Stage of Commercialization with Differentiated Advantages Differentiated Clinical Differentiated 865M RMB Antibody Advantages Indications • In March 2023, HANSIZHUANG • HANSIZHUANG (serplulimab) HANSIZHUANG recommended by 9 ES-SCLC (Marketed): achieved over

  7. Slide 7: R&D for Innovative Drugs: Beyond Oncology, Expanding into New TAs for UMN

    R&D for Innovative Drugs: Beyond Oncology, Expanding into New TAs for UMN Product Type & Introduction Innovative Pipeline Distribution by Stage (by Molecule) 32 ✓ Total 63 molecules in pipeline with 49 innovative drugs and 14 biosimilars ✓ Pipeline focuses around oncology while starting to explore n

  8. Slide 8: Commercialization

    02 Commercialization © 2023 Henlius

  9. Slide 9: HANQUYOU (Trastuzumab): 3Q23 Sales Growth 52% YoY

    HANQUYOU (Trastuzumab): 3Q23 Sales Growth 52% YoY International quality Strong growth momentum 738M RMB* • • First approved trastuzumab biosimilar in China First “Chinese nationality” mAb biosimilar approved +55% In Billion RMB in Europe 3Q 2023 Revenue • BLA under FDA review; expected to be the fir

  10. Slide 10: Excellent Performance of HANQUYOU

    Excellent Performance of HANQUYOU Strengthen product Higher sales per capita The only trastuzumab advantage to build Develop Broad market than domestic peers with two specifications competition advantage Sales Per Capita* • 2 specifications were • As more local trastuzumab • Trastuzumab is widely us

  11. Slide 11: HANSIZHUANG (Serplulimab): First Global PD-1 mAb for SCLC 1L Treatment

    HANSIZHUANG (Serplulimab): First Global PD-1 mAb for SCLC 1L Treatment Differentiated strategies to seize the 309M RMB Widespread recognition market • MAA for 1L ES-SCLC indication is under EMA review • Developed differentiated marketing strategies and 3Q 2023 Revenue focused on SCLC to rapidly incr

  12. Slide 12: HANSIZHUANG Commercialization Highlights

    HANSIZHUANG Commercialization Highlights High Market Share Driven by First-class Commercialization Efficiency Differentiation Strategy Outstanding Achievements Differentiation Strategy • Sales outperformed most of the competing PD- 1/PD-L1 since its launch in 2021 Focus on SCLC 865M RMB • Expected t

  13. Slide 13: HANBEITAI (Bevacizumab): Commercialization Acceleration in 2023

    HANBEITAI (Bevacizumab): Commercialization Acceleration in 2023 36M RMB Acceleration on market access and penetration Exploration for new medication methods 3Q 2023 Revenue • Covered by NRDL in 31 provinces, and completed tendering and procurement platform • The only bevacizumab biosimilars with pha

  14. Slide 14: HANLIKANG (Rituximab): Strengthen the Market Leader Position

    HANLIKANG (Rituximab): Strengthen the Market Leader Position Acceleration on market access Commercialization Progress and penetration 131M RMB • Approved in February 2019 as the first approved • Jiangsu Fosun, a subsidiary of Fosun Pharma, is biosimilar in China, the first approved rituximab respons

  15. Slide 15: HANDAYUAN (Adalimumab): Entered Autoimmune Disease Area

    HANDAYUAN (Adalimumab): Entered Autoimmune Disease Area Improve patients’ availability and Work with partners to penetrate the 11M RMB accessibility market 3Q 2023 revenue recognized by Henlius • Henlius’ first autoimmune disease product • Jiangsu Wanbang is responsible for China-region sales of • C

  16. Slide 16: Business Development

    03 Business Development © 2023 Henlius

  17. Slide 17: Collaboration Expansion with Existing Partner about HLX10 EU & India

    Collaboration Expansion with Existing Partner about HLX10 EU & India Intas Pharmaceuticals Limited1 Oncology Leader 30% volume share of major chemotherapy molecules in key geographies Pharmaceutical Major US$2.5Bn global sales FY2022 Global Presence Sales derived from 85+ countries with 60% from EU

  18. Slide 18: Collaboration Expansion with Existing Partner about HLX10 EU & India

    Collaboration Expansion with Existing Partner about HLX10 EU & India Upfronts up to €42 million* HANSIZHUANG (serplulimab) Deal size €185 million Covering EU & India 50+ countries • Since 2018, Intas/Accord started cooperation with Henlius on the registration, technology transfer and commercial laun

  19. Slide 19: Research & Development

    04 Research & Development © 2023 Henlius

  20. Slide 20: Product Pipeline

    Product Pipeline Pre-clinical IND Phase I Phase II Phase III NDA In-Market HLX61 HLX51 HLX10(1) (serplulimab)+HLX60(2) HLX10(1) (serplulimab)+HANBEITAI HLX10(1) (serplulimab)+chemo HLX10(1) (serplulimab)+chemo HANSIZHUANG (serplulimab) (1) Undisclosed (tumor immunity) OX40 PD-1+GARP PD-1+VEGF PD-1 P

  21. Slide 21: Clinical Pipeline Milestones: YTD 3Q 2023 Review

    Clinical Pipeline Milestones: YTD 3Q 2023 Review YTD 3Q 2023 HLX10 HLX10 ES-SCLC1 ES-SCLC 1L (EU) 1L (Indonesia, Myanmar, Cambodia) NDA/BLA/MAA Submission HLX10 HLX07+HLX10 sqNSCLC2 ESCC3 Final OS results 1L, 2L and late-line (PoC) 1L (Pivotal) ‘ Key Clinical Data HLX208 Readouts BRAF V600E LCH/ECD4

  22. Slide 22: Clinical Pipeline Milestones: 2023-2024 (expected)

    Clinical Pipeline Milestones: 2023-2024 (expected) 4Q 2023 2024 HLX10 HLX04-O ES-SCLC Wet AMD3 HLX10 1L (US, Vietnam) 1L (CN) HLX10 ES-SCLC2 nsNSCLC1 1L (Malaysia, Thailand, 1L (CN) HLX11 HLX14 Singapore, Philippines ) NDA/BLA/MAA Neoadjuvant treatment of PMOP4 breast cancer (US) (EU & US) Submissio

  23. Slide 23: HLX11 and HLX14: Multi-Regional Phase III Clinical Trials Ongoing

    HLX11 and HLX14: Multi-Regional Phase III Clinical Trials Ongoing HLX11 – Pertuzumab Biosimilar HLX14 – Denosumab Biosimilar • Focusing on China, the US and Europe, the MRCT1 • As the first China-made denosumab biosimilar aiming plans to enrol 900 patients globally, expected to be the to be approved

  24. Slide 24: Serplulimab: Targeting Differentiated Indications

    Serplulimab: Targeting Differentiated Indications According to the baseline data analysis of 649 subjects in the Checkmate, 60% advanced GC patients had CPS ≥ 5. The trial design had focused on PD-L1-positive patients (CPS ≥ 5) from Gastric Cancer the very beginning. Serplulimab aims to be first per

  25. Slide 25: HLX07: Address Unmet Medical Needs of High EGFR Expression Patients

    HLX07: Address Unmet Medical Needs of High EGFR Expression Patients ESCC Study Design (Phase II) HLX07 Indication Profile (Phase II) Inclusion Criteria: Group A (1L) • Age 18-75 years; ECOG PS 0 or 1 HLX07, 1000 mg; Serplulimab, 200 mg; Chemotherapy • ESCC or esophageal adenosquamous carcinoma Q2W I

  26. Slide 26: HLX22: Potential to Change the SOC of 1L GC

    HLX22: Potential to Change the SOC of 1L GC HLX22 (HER2) • HLX22 targets at different epitopes within domain IV of HER2 Anti-HER2 mAb • PDx data shows HLX22 & trastuzumab combo has more advantages than trastuzumab & pertuzumab combo in GC • Current SOC of 1L mGC/GJC treatment Trastuzumab + chemo app

  27. Slide 27: R&D: Pre-clinical Assets

    4.1 R&D: Pre-clinical Assets © 2023 Henlius

  28. Slide 28: Antibody Drug Conjugate (ADC) R&D Platform: Hanjugator

    Antibody Drug Conjugate (ADC) R&D Platform: HanjugatorTM Develop differentiated Increase the efficacy of Improve safety and Enhance the selectivity Expand the application ADC products: ADCs: develop therapeutic window of of ADCs: build Tumor scenarios of ADCs: establish a new Multiple-Payloads ADC A

  29. Slide 29: Innovative Antibody Drug Conjugate (ADC): HLX42 and HLX43

    Innovative Antibody Drug Conjugate (ADC): HLX42 and HLX43 • The IND applications of HLX42 EGFR ADC and HLX43 PD-L1 ADC have been approved by the NMPA, and the phase 1 clinical trials will be initiated. • The results of the preclinical studies of these two ADC candidates were published as poster pres

  30. Slide 30: 5D Platform Targeting Oncology, Metabolism, Immunity and Neurology

    5D Platform Targeting Oncology, Metabolism, Immunity and Neurology Based on the Deep Data Driven Drug Discovery (5D) Driven by the Biocomputing Accelerated Molecule platform, integrate medical informatic data to discover Design (BAMD) platform, design new drug molecules new targets, mechanisms and d

  31. Slide 31: Manufacturing

    05 Manufacturing © 2023 Henlius

  32. Slide 32: International Leading Capabilities on Manufacturing and Quality Management

    International Leading Capabilities on Manufacturing and Quality Management Xuhui Site Songjiang Songjiang 1st Plant 2nd Plant • Manufacturing capacity optimization: • Increasing supply of HANQUYOU • Plant construction for Phase I & II trials: The scale of commercial GMP batches has (trastuzumab): Ov

  33. Slide 33: Operation Excellence and Continuous Innovation

    Operation Excellence and Continuous Innovation Technical Innovation Lean Operations • Reached key milestone of using Lean • 34 on-going lean operations domestic production consumables Operations projects with ~10M RMB expected and completed commercial scale annualized returns process validation • Th

  34. Slide 34: 3Q 2023 Financial Review

    06 3Q 2023 Financial Review © 2023 Henlius

  35. Slide 35: 3Q 2023 Revenue of RMB 1.43 Billion with 69.0% YoY

    3Q 2023 Revenue of RMB 1.43 Billion with 69.0% YoY Revenue Product Sales 3Q 2023 Revenue Breakdown (in Million RMB) (in Million RMB) (in Million RMB) 800.0 60.0% 737.7 1,427.3 700.0 3Q 22 51.7% 50.0% 1,225.5 69.0% 55.9% 600.0 3Q 23 485.4 40.0% 500.0 3Q 23 Share % 844.8 786.2 400.0 30.0% 82.8% 72.5%

  36. Slide 36: Achieved Profitability in 3Q 2023 with RMB ~240M Operating CF

    Achieved Profitability in 3Q 2023 with RMB ~240M Operating CF Net profit (net loss) excl. extraordinary items R&D investment (in Million RMB) (in Million RMB) 3Q 21 3Q 22 3Q 23 545 200.00 146.0 20.0% 150.00 10.2% 10.0% 176.1 100.00 50.00 0.0% 301 0.00 -10.0% -50.00 31.1 -100.00 -20.0% -22.8% -150.00

  37. Slide 37: Financial Highlights

    Financial Highlights Financial Data 3Q 23 3Q 22 YoY Growth YTD 3Q 23 (selected) Unit In Million RMB % of revenue In Million RMB % of revenue % In Million RMB % of revenue Revenue 1,427.34 100.00% 844.83 100.00% 68.95% 3,927.81 100.00% Product sales 1,225.50 85.86% 786.17 93.06% 55.88% 3,378.41 86.01

  38. Slide 38: 2023 Performance Outlook

    07 2023 Performance Outlook © 2023 Henlius

  39. Slide 39: Our Goals for 2023

    Our Goals for 2023 Revenue: rapid growth driven by promoting clinical advantage of HANSIZHUANG and HANQUYOU Profitability: improve P&L level, and improve profits from internal operation Cashflow: positive OCF generated for the past two years; strengthen organic growth in 2023 and build strong and he

  40. Slide 40: Disclaimer

    声明 Disclaimer • 复宏汉霖、陈述人或提供人对本文件内容(文件内容亦有可能包括前瞻性陈述)均不做出明示或默示的保证、声明或陈述(包括但不限于:本内容针对为任意特定目的而关于内容 所具有的及时性、通用性、精确性的声明,或者关于使用本文件内容所获得信息无误可信的声明)。如因有关内容存在错误、遗漏或失准之处而引致的行为或结果,复宏汉霖、陈 述人或提供人对此不承担责任。 • 本文件及其中所包含内容的所有权利包括版权均由复宏汉霖独家所有,其中相关的“Henlius” 和“复宏汉霖”字样、图案及相关LOGO标识均为复宏汉霖合法所有的字号、商标和 标识。未经复宏汉霖书面同意,任何第三方不得以包括

  41. Slide 41: © 2023 Henlius

    A | Henlius #22:3V% ARENA Sia Mio Reliable Quality Affordable Innovation

Shanghai Henlius Biotech — Q3 2023 Earnings Presentation on 6ix